Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
To date, there are no clinically effective neuroprotective or disease-modifying treatments that can halt Parkinson's disease (PD) progression. The current clinical approach focuses on symptomatic management. This failure may relate to the complex neurobiology underpinning the development of PD...
Main Authors: | Carolina Sportelli, Daniele Urso, Peter Jenner, K. Ray Chaudhuri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00556/full |
Similar Items
-
Editorial: Prodromal Parkinson's Disease
by: David Crosiers, et al.
Published: (2021-01-01) -
Animal Model for Prodromal Parkinson’s Disease
by: Tomoyuki Taguchi, et al.
Published: (2020-03-01) -
Clinical and Imaging Markers of Prodromal Parkinson's Disease
by: Eldbjørg Hustad, et al.
Published: (2020-05-01) -
Traumatic Brain Injury During the Prodromal Phase of Parkinson’s Disease
by: Halil Önder
Published: (2018-06-01) -
Diagnostic Criteria for Parkinson’s Disease: From James Parkinson to the Concept of Prodromal Disease
by: Luca Marsili, et al.
Published: (2018-03-01)